Morbidity and Disability in Juvenile Localized Scleroderma: The Case for Early Recognition and Systemic Immunosuppressive Treatment

J Pediatr. 2021 Jul:234:245-256.e2. doi: 10.1016/j.jpeds.2021.01.068. Epub 2021 Feb 3.

Authors

Suzanne C Li¹, Kathleen M O'Neil², Gloria C Higgins³

Affiliations

¹ Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack Meridian School of Medicine, Hackensack, NJ. Electronic address: [email protected].
² Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN.
³ Department of Pediatrics, Division of Rheumatology, The Ohio State University and Nationwide Children's Hospital, Columbus, OH.

PMID: 33548257
DOI: 10.1016/j.jpeds.2021.01.068

No abstract available

Publication types

Review

MeSH terms

Adolescent
Child
Child Development
Child, Preschool
Disabled Persons
Disease Progression
Early Diagnosis
Humans
Immunosuppressive Agents / therapeutic use
Scleroderma, Localized / diagnosis
Scleroderma, Localized / drug therapy
Scleroderma, Localized / pathology
Scleroderma, Localized / physiopathology*
Time-to-Treatment
Treatment Outcome

Substances

Immunosuppressive Agents